Access cutting-edge lennox gastaut syndrome treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access lennox gastaut syndrome specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lennox gastaut syndrome treatment provided free
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Sponsor: SK Life Science, Inc.
Check if you qualify for this lennox gastaut syndrome clinical trial in Palo Alto, CA
If you're searching for lennox gastaut syndrome treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lennox gastaut syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.